A strategic agreement for the commercialisation of Newron’s lead compound safinamide for the treatment of Parkinson’s disease in the U.S. has been signed among Zambon and US-based WorldMeds.
The Italian company holds the global marketing rights for safinamide with the exception of Japan/Asia and has recently begun the commercialization of the product in the EU and Switzerland. The New Drug Application (NDA) for safinamide has been accepted for review by the U.S. Food and Drug Administration (FDA).